Neuromyelitis optica (NMOSD): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• AQP4 11
• CD20 4
• CD19 6
• BCMA 8
• IL-6 0
• STAT3 0
• STING 0
• TIM-3 0
• APOE 0
• BTK 0
• FOXP3 0
• IGF1R 0
• IL-1 0
• PD-1 0
• PD-L1 0
• PI3K 0
• PPAR 0
• TIGIT 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

5 of 5+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

  NCT07247292· AstraZeneca· Updated 21 Jul 2026

  “The decision is based on strategic deprioritization and is not related to any safety concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

• A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT05199688· Hoffmann-La Roche· Source

• Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD

  2023-508534-33-00· Alexion Pharmaceuticals Inc.· Source

• Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

  NCT07247292· AstraZeneca· Source

• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

  NCT05346354· Alexion Pharmaceuticals, Inc.· Source

• lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder

  2024-517176-38-00· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

  NCT06724809· Alexion Pharmaceuticals, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 5
• Gene Expression Profiling 2
• Proteomics 3
• Metabolomics 2
• Flow Cytometry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 83
• Machine Learning 3
• Deep Learning 1
• Cohort Studies 23
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.